Appili Therapeutics Valuation
| APLI Stock | CAD 0.03 0.01 14.29% |
Appili Therapeutics seems to be overvalued based on Macroaxis valuation methodology. Our model approximates the value of Appili Therapeutics from analyzing the firm fundamentals such as Shares Outstanding of 121.27 M, operating margin of (10.40) %, and Return On Equity of -9.39 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Appili Therapeutics' valuation include:
Price Book 1.3981 | Enterprise Value | Enterprise Value Ebitda (3.61) | Price Sales 34.0236 | Forward PE 2.3776 |
Overvalued
Today
Please note that Appili Therapeutics' price fluctuation is out of control at this time. Calculation of the real value of Appili Therapeutics is based on 3 months time horizon. Increasing Appili Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Appili Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Appili Stock. However, Appili Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.03 | Real 0.0273 | Hype 0.03 |
The intrinsic value of Appili Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Appili Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Appili Therapeutics helps investors to forecast how Appili stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Appili Therapeutics more accurately as focusing exclusively on Appili Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Appili Therapeutics' intrinsic value based on its ongoing forecasts of Appili Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Appili Therapeutics' closest peers.
Appili Therapeutics Cash |
|
Appili Valuation Trend
Knowing Appili Therapeutics' actual value is paramount for traders when making sound investment determinations. Using both Appili Therapeutics' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Appili Therapeutics Total Value Analysis
Appili Therapeutics is presently estimated to have takeover price of 15.34 M with market capitalization of 4.24 M, debt of 8.18 M, and cash on hands of 5.55 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Appili Therapeutics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
15.34 M | 4.24 M | 8.18 M | 5.55 M |
Appili Therapeutics Investor Information
The company has price-to-book (P/B) ratio of 1.4. Some equities with similar Price to Book (P/B) outperform the market in the long run. Appili Therapeutics recorded a loss per share of 0.03. The entity had not issued any dividends in recent years. Based on the key indicators related to Appili Therapeutics' liquidity, profitability, solvency, and operating efficiency, Appili Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Appili Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Appili Therapeutics has an asset utilization ratio of 55.52 percent. This suggests that the Company is making C$0.56 for each dollar of assets. An increasing asset utilization means that Appili Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Appili Therapeutics Ownership Allocation
Appili Therapeutics holds a total of 121.27 Million outstanding shares. Almost 88.1 percent of Appili Therapeutics outstanding shares are held by general public with 0.06 (percent) owned by insiders and only 11.84 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Appili Therapeutics Profitability Analysis
The company reported the revenue of 827.41 K. Net Loss for the year was (3.78 M) with profit before overhead, payroll, taxes, and interest of 1.39 M.About Appili Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Appili Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Appili Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Appili Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Appili Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Appili Therapeutics. We calculate exposure to Appili Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Appili Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 935.8 K | 982.6 K | |
| Pretax Profit Margin | (4.04) | (4.24) | |
| Operating Profit Margin | (8.76) | (9.19) | |
| Net Loss | (4.11) | (4.32) | |
| Gross Profit Margin | 0.88 | 0.78 |
Other Information on Investing in Appili Stock
Appili Therapeutics financial ratios help investors to determine whether Appili Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Appili with respect to the benefits of owning Appili Therapeutics security.